Hypothalamic obesity caused by cranial insult in children: Altered glucose and insulin dynamics and reversal by a somatostatin agonist

R. H. Lustig, S. R. Rose, G. A. Burghen, P. Velasquez-Mieyer, D. C. Broome, K. Smith, H. Li, M. M. Hudson, R. L. Heideman, L. E. Kun

Research output: Contribution to journalArticle

127 Citations (Scopus)

Abstract

Objective: Hypothalamic obesity is a rare sequela of cranial insult, for which pathogenesis and treatment remain obscure. In rodents ventromedial hypothalamic damage causes hyperphagia, obesity, hyperinsulinism, and insulin resistance. Reduction of insulin secretion in humans may attenuate weight gain. Methods: Eight children with intractable obesity after therapy for leukemia or brain tumors underwent oral glucose tolerance testing (OGTT) with simultaneous insulin levels before and after treatment with octreotide for 6 months. Results: In comparison with a 6-month pre-study observation period, patients exhibited weight loss (+6.0 ± 0.7 kg vs -4.8 ± 1.8 kg; P = .04) and decrease in body mass index (+2.1 ± 0.3 kg/m2 vs -2.0 ± 0.7 kg/m2; P = .0001). Recall calorie count decreased during the 6 months of treatment (P = .015). OGTT demonstrated biochemical glucose intolerance in 5 of 8 patients initially and in 2 of 7 at study end, whereas insulin response was decreased (281 ± 47 μU/mL vs 114 ± 35 μU/mL; P = .04). Percent weight change correlated with changes in insulin response (r = 0.72, P = .012) and changes in plasma leptin r = 0.76, P = .0004). Conclusions: Patients with hypothalamic obesity demonstrate excessive insulin secretion. Octreotide administration promoted weight loss, which correlated with reduction in insulin secretion on OGTT and with reduction in leptin levels. Pre-study biochemical glucose tolerance improved in several patients while they were receiving octreotide. These results suggest that normalization of insulin secretion may be an effective therapeutic strategy in this syndrome.

Original languageEnglish (US)
Pages (from-to)162-168
Number of pages7
JournalJournal of Pediatrics
Volume135
Issue number2 I
StatePublished - Dec 1 1999

Fingerprint

Somatostatin
Obesity
Insulin
Glucose
Octreotide
Glucose Tolerance Test
Leptin
Weight Loss
Therapeutics
Hyperphagia
Glucose Intolerance
Hyperinsulinism
Brain Neoplasms
Weight Gain
Insulin Resistance
Rodentia
Leukemia
Body Mass Index
Observation
Weights and Measures

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Lustig, R. H., Rose, S. R., Burghen, G. A., Velasquez-Mieyer, P., Broome, D. C., Smith, K., ... Kun, L. E. (1999). Hypothalamic obesity caused by cranial insult in children: Altered glucose and insulin dynamics and reversal by a somatostatin agonist. Journal of Pediatrics, 135(2 I), 162-168.

Hypothalamic obesity caused by cranial insult in children : Altered glucose and insulin dynamics and reversal by a somatostatin agonist. / Lustig, R. H.; Rose, S. R.; Burghen, G. A.; Velasquez-Mieyer, P.; Broome, D. C.; Smith, K.; Li, H.; Hudson, M. M.; Heideman, R. L.; Kun, L. E.

In: Journal of Pediatrics, Vol. 135, No. 2 I, 01.12.1999, p. 162-168.

Research output: Contribution to journalArticle

Lustig, RH, Rose, SR, Burghen, GA, Velasquez-Mieyer, P, Broome, DC, Smith, K, Li, H, Hudson, MM, Heideman, RL & Kun, LE 1999, 'Hypothalamic obesity caused by cranial insult in children: Altered glucose and insulin dynamics and reversal by a somatostatin agonist', Journal of Pediatrics, vol. 135, no. 2 I, pp. 162-168.
Lustig RH, Rose SR, Burghen GA, Velasquez-Mieyer P, Broome DC, Smith K et al. Hypothalamic obesity caused by cranial insult in children: Altered glucose and insulin dynamics and reversal by a somatostatin agonist. Journal of Pediatrics. 1999 Dec 1;135(2 I):162-168.
Lustig, R. H. ; Rose, S. R. ; Burghen, G. A. ; Velasquez-Mieyer, P. ; Broome, D. C. ; Smith, K. ; Li, H. ; Hudson, M. M. ; Heideman, R. L. ; Kun, L. E. / Hypothalamic obesity caused by cranial insult in children : Altered glucose and insulin dynamics and reversal by a somatostatin agonist. In: Journal of Pediatrics. 1999 ; Vol. 135, No. 2 I. pp. 162-168.
@article{7f5fd53ef4d6417f9045c31f86562347,
title = "Hypothalamic obesity caused by cranial insult in children: Altered glucose and insulin dynamics and reversal by a somatostatin agonist",
abstract = "Objective: Hypothalamic obesity is a rare sequela of cranial insult, for which pathogenesis and treatment remain obscure. In rodents ventromedial hypothalamic damage causes hyperphagia, obesity, hyperinsulinism, and insulin resistance. Reduction of insulin secretion in humans may attenuate weight gain. Methods: Eight children with intractable obesity after therapy for leukemia or brain tumors underwent oral glucose tolerance testing (OGTT) with simultaneous insulin levels before and after treatment with octreotide for 6 months. Results: In comparison with a 6-month pre-study observation period, patients exhibited weight loss (+6.0 ± 0.7 kg vs -4.8 ± 1.8 kg; P = .04) and decrease in body mass index (+2.1 ± 0.3 kg/m2 vs -2.0 ± 0.7 kg/m2; P = .0001). Recall calorie count decreased during the 6 months of treatment (P = .015). OGTT demonstrated biochemical glucose intolerance in 5 of 8 patients initially and in 2 of 7 at study end, whereas insulin response was decreased (281 ± 47 μU/mL vs 114 ± 35 μU/mL; P = .04). Percent weight change correlated with changes in insulin response (r = 0.72, P = .012) and changes in plasma leptin r = 0.76, P = .0004). Conclusions: Patients with hypothalamic obesity demonstrate excessive insulin secretion. Octreotide administration promoted weight loss, which correlated with reduction in insulin secretion on OGTT and with reduction in leptin levels. Pre-study biochemical glucose tolerance improved in several patients while they were receiving octreotide. These results suggest that normalization of insulin secretion may be an effective therapeutic strategy in this syndrome.",
author = "Lustig, {R. H.} and Rose, {S. R.} and Burghen, {G. A.} and P. Velasquez-Mieyer and Broome, {D. C.} and K. Smith and H. Li and Hudson, {M. M.} and Heideman, {R. L.} and Kun, {L. E.}",
year = "1999",
month = "12",
day = "1",
language = "English (US)",
volume = "135",
pages = "162--168",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "2 I",

}

TY - JOUR

T1 - Hypothalamic obesity caused by cranial insult in children

T2 - Altered glucose and insulin dynamics and reversal by a somatostatin agonist

AU - Lustig, R. H.

AU - Rose, S. R.

AU - Burghen, G. A.

AU - Velasquez-Mieyer, P.

AU - Broome, D. C.

AU - Smith, K.

AU - Li, H.

AU - Hudson, M. M.

AU - Heideman, R. L.

AU - Kun, L. E.

PY - 1999/12/1

Y1 - 1999/12/1

N2 - Objective: Hypothalamic obesity is a rare sequela of cranial insult, for which pathogenesis and treatment remain obscure. In rodents ventromedial hypothalamic damage causes hyperphagia, obesity, hyperinsulinism, and insulin resistance. Reduction of insulin secretion in humans may attenuate weight gain. Methods: Eight children with intractable obesity after therapy for leukemia or brain tumors underwent oral glucose tolerance testing (OGTT) with simultaneous insulin levels before and after treatment with octreotide for 6 months. Results: In comparison with a 6-month pre-study observation period, patients exhibited weight loss (+6.0 ± 0.7 kg vs -4.8 ± 1.8 kg; P = .04) and decrease in body mass index (+2.1 ± 0.3 kg/m2 vs -2.0 ± 0.7 kg/m2; P = .0001). Recall calorie count decreased during the 6 months of treatment (P = .015). OGTT demonstrated biochemical glucose intolerance in 5 of 8 patients initially and in 2 of 7 at study end, whereas insulin response was decreased (281 ± 47 μU/mL vs 114 ± 35 μU/mL; P = .04). Percent weight change correlated with changes in insulin response (r = 0.72, P = .012) and changes in plasma leptin r = 0.76, P = .0004). Conclusions: Patients with hypothalamic obesity demonstrate excessive insulin secretion. Octreotide administration promoted weight loss, which correlated with reduction in insulin secretion on OGTT and with reduction in leptin levels. Pre-study biochemical glucose tolerance improved in several patients while they were receiving octreotide. These results suggest that normalization of insulin secretion may be an effective therapeutic strategy in this syndrome.

AB - Objective: Hypothalamic obesity is a rare sequela of cranial insult, for which pathogenesis and treatment remain obscure. In rodents ventromedial hypothalamic damage causes hyperphagia, obesity, hyperinsulinism, and insulin resistance. Reduction of insulin secretion in humans may attenuate weight gain. Methods: Eight children with intractable obesity after therapy for leukemia or brain tumors underwent oral glucose tolerance testing (OGTT) with simultaneous insulin levels before and after treatment with octreotide for 6 months. Results: In comparison with a 6-month pre-study observation period, patients exhibited weight loss (+6.0 ± 0.7 kg vs -4.8 ± 1.8 kg; P = .04) and decrease in body mass index (+2.1 ± 0.3 kg/m2 vs -2.0 ± 0.7 kg/m2; P = .0001). Recall calorie count decreased during the 6 months of treatment (P = .015). OGTT demonstrated biochemical glucose intolerance in 5 of 8 patients initially and in 2 of 7 at study end, whereas insulin response was decreased (281 ± 47 μU/mL vs 114 ± 35 μU/mL; P = .04). Percent weight change correlated with changes in insulin response (r = 0.72, P = .012) and changes in plasma leptin r = 0.76, P = .0004). Conclusions: Patients with hypothalamic obesity demonstrate excessive insulin secretion. Octreotide administration promoted weight loss, which correlated with reduction in insulin secretion on OGTT and with reduction in leptin levels. Pre-study biochemical glucose tolerance improved in several patients while they were receiving octreotide. These results suggest that normalization of insulin secretion may be an effective therapeutic strategy in this syndrome.

UR - http://www.scopus.com/inward/record.url?scp=0033497369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033497369&partnerID=8YFLogxK

M3 - Article

C2 - 10431109

AN - SCOPUS:0033497369

VL - 135

SP - 162

EP - 168

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 2 I

ER -